

Kathleen E Corey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8561419/publications.pdf>

Version: 2024-02-01

115
papers

5,295
citations

81900

39
h-index

102487

66
g-index

124
all docs

124
docs citations

124
times ranked

7495
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocyte TAZ/WVTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2016, 24, 848-862.	16.2	279
2	AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2021, 160, 912-918.	1.3	245
3	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 903-913.	8.1	227
4	Secondary causes of nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 199-207.	3.2	205
5	Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1683.	7.1	170
6	Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. <i>Hepatology</i> , 2009, 50, 1030-1037.	7.3	169
7	The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 491-500.	1.2	153
8	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 406-421.e7.	16.2	141
9	Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. <i>Journal of Clinical Investigation</i> , 2017, 127, 4394-4402.	8.2	115
10	Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2776-2784.e4.	4.4	108
11	Advanced fibrosis is associated with incident cardiovascular disease in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 728-736.	3.7	104
12	Obesity and Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 1-18.	2.1	103
13	Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. <i>Hepatology</i> , 2018, 67, 1797-1806.	7.3	100
14	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. <i>Diabetes and Metabolism</i> , 2021, 47, 101215.	2.9	84
15	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. <i>Hepatology</i> , 2017, 65, 1156-1164.	7.3	76
16	The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. <i>Liver International</i> , 2009, 29, 748-753.	3.9	75
17	Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 920-928.	7.3	70
18	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. <i>Gastroenterology</i> , 2021, 160, 1620-1633.e13.	1.3	68

#	ARTICLE	IF	CITATIONS
19	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2108-2117.	2.3	67
20	Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2592-2599.	4.4	67
21	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	3.7	66
22	Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. <i>Infectious Diseases</i> , 2015, 47, 924-929.	2.8	63
23	Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record. <i>Digestive Diseases and Sciences</i> , 2016, 61, 913-919.	2.3	63
24	Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity. <i>JAMA Surgery</i> , 2017, 152, 136.	4.3	62
25	Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. <i>JCI Insight</i> , 2017, 2, .	5.0	62
26	The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e217.	2.5	61
27	Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. <i>Obesity</i> , 2017, 25, 1313-1316.	3.0	59
28	A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. <i>Scientific Reports</i> , 2015, 5, 18277.	3.3	58
29	Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. <i>International Journal of Cardiology</i> , 2018, 259, 198-204.	1.7	53
30	Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1480-1488.e14.	4.4	53
31	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , 2018, 270, 245-252.	1.7	51
32	The MELD-Plus: A generalizable prediction risk score in cirrhosis. <i>PLoS ONE</i> , 2017, 12, e0186301.	2.5	51
33	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. <i>Lancet HIV</i> , 2019, 6, e821-e830.	4.7	50
34	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. <i>Hepatology</i> , 2021, 73, 548-559.	7.3	49
35	Outcomes and Treatment of Acute Hepatitis C Virus Infection in a United States Population. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1278-1282.	4.4	48
36	Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2523-2528.	2.3	46

#	ARTICLE	IF	CITATIONS
37	Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e520-e533.	3.6	43
38	Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e114.	2.5	42
39	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e190047.	5.9	42
40	Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. <i>Liver Transplantation</i> , 2019, 25, 859-869.	2.4	40
41	Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <i>Hepatology Communications</i> , 2021, 5, 133-143.	4.3	39
42	Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis. <i>PLoS ONE</i> , 2012, 7, e27144.	2.5	38
43	Non-High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 651-656.	4.4	37
44	Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1077-1084.	4.4	36
45	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2018, 218, 1394-1403.	4.0	36
46	Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. <i>Scientific Reports</i> , 2021, 11, 18045.	3.3	36
47	Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. <i>Lipids in Health and Disease</i> , 2014, 13, 100.	3.0	35
48	Population attributable fraction of Esophageal squamous cell carcinoma due to smoking and alcohol in Uganda. <i>BMC Cancer</i> , 2016, 16, 446.	2.6	35
49	Biomass fuel as a risk factor for esophageal squamous cell carcinoma: a systematic review and meta-analysis. <i>Environmental Health</i> , 2019, 18, 60.	4.0	35
50	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	4.4	34
51	ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 25-33.	3.7	34
52	Machine learning enables new insights into genetic contributions to liver fat accumulation. <i>Cell Genomics</i> , 2021, 1, 100066.	6.5	34
53	Improvement in Liver Histology Is Associated With Reduction in Dyslipidemia in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015, 60, 360-367.	1.8	33
54	Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1387-1397.	2.3	32

#	ARTICLE	IF	CITATIONS
55	Treatment of Dyslipidemia in Common Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1189-1196.	4.4	32
56	Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. <i>Journal of Hepatology</i> , 2020, 72, 1062-1069.	3.7	32
57	Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. <i>American Journal of Transplantation</i> , 2020, 20, 1619-1628.	4.7	31
58	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. <i>Clinical Liver Disease</i> , 2021, 17, 19-22.	2.1	31
59	Hepatocellular Carcinoma Screening Rates Vary by Etiology of Cirrhosis and Involvement of Gastrointestinal Sub-specialists. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3316-3322.	2.3	29
60	Intermittent hypoxia is a proinflammatory stimulus resulting in IL-6 expression and M1 macrophage polarization. <i>Hepatology Communications</i> , 2017, 1, 326-337.	4.3	29
61	Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1297-1310.	4.5	28
62	TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2022, 76, 910-920.	3.7	27
63	Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis. <i>Hepatology</i> , 2019, 70, 496-510.	7.3	25
64	Distinct Hepatic Gene Expression Patterns of NAFLD in Patients With Obesity. <i>Hepatology Communications</i> , 2022, 6, 77-89.	4.3	25
65	Gaps in Recognition and Evaluation of Incidentally Identified Hepatic Steatosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 333-338.	2.3	24
66	Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein subfractions: a post-hoc analysis of the PIVENS trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1205-1213.	3.7	24
67	Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver. <i>Hepatology</i> , 2020, 72, 857-872.	7.3	24
68	Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 671-676.	0.4	22
69	Pilot Study of Postexposure Prophylaxis for Hepatitis C Virus in Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 1000-1005.	1.8	21
70	Comparing Outcomes of Two Types of Bariatric Surgery in an Adolescent Obese Population: Roux-en-Y Gastric Bypass vs. Sleeve Gastrectomy. <i>Frontiers in Pediatrics</i> , 2016, 4, 78.	1.9	21
71	Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 1125-1133.	1.5	19
72	Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 843-849.	1.2	19

#	ARTICLE	IF	CITATIONS
73	Advanced Disease, Diuretic Use, and Marital Status Predict Hospital Admissions in an Ambulatory Cirrhosis Cohort. <i>Digestive Diseases and Sciences</i> , 2014, 59, 174-182.	2.3	18
74	Plasma Free Cortisol in States of Normal and Altered Binding Globulins: Implications for Adrenal Insufficiency Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4827-4836.	3.6	18
75	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	7.3	17
76	Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 120, 154780.	3.4	17
77	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	12.4	17
78	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	1.3	17
79	Review: Current status of therapy for hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 45-57.	3.2	15
80	Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 2087-2094.	5.8	15
81	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	7.3	15
82	The Absence of Obstructive Sleep Apnea May Protect against Non-Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery. <i>PLoS ONE</i> , 2013, 8, e62504.	2.5	14
83	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3425-3435.	2.3	14
84	Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. <i>World Journal of Hepatology</i> , 2017, 9, 385.	2.0	14
85	Statin therapy in patients with cirrhosis. <i>Frontline Gastroenterology</i> , 2015, 6, 255-261.	1.8	13
86	Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. <i>JCI Insight</i> , 2020, 5, .	5.0	13
87	Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart. <i>Hepatology</i> , 2020, 71, 1867-1869.	7.3	12
88	Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. <i>Hepatology Communications</i> , 2022, 6, 2581-2593.	4.3	12
89	Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 309-319.	4.3	11
90	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e114747.	2.5	11

#	ARTICLE	IF	CITATIONS
91	The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 9831.	3.3	10
92	Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 400-404.	2.1	10
93	Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 972-980.	1.5	10
94	Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 292-298.	1.2	10
95	Model for end-stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 429-438.	4.3	9
96	Nonalcoholic fatty liver disease and gastric bypass surgery regulate serum and hepatic levels of pyruvate kinase isoenzyme M2. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E613-E621.	3.5	9
97	Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis. <i>Gastroenterology</i> , 2020, 159, 2232-2234.e4.	1.3	7
98	Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2021, 73, 621-630.	5.8	7
99	Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. <i>Scientific Reports</i> , 2021, 11, 10485.	3.3	6
100	Interpretation of abnormal liver chemistries in the hospitalized patient. <i>Clinical Liver Disease</i> , 2016, 7, 132-134.	2.1	5
101	Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1452-1460.	2.3	5
102	Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2012, 1, 114-116.	2.1	4
103	Managing the Burden of Non-NASH NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 326-334.	0.9	3
104	Lessons Learned From and Future Opportunities for Global Health Endeavors by 2 Academic Gastroenterology Units. <i>Gastroenterology</i> , 2019, 157, 1177-1179.	1.3	3
105	Treatment of Dyslipidemia in Common Liver Diseases. <i>Clinical Liver Disease</i> , 2019, 14, 161-162.	2.1	3
106	Bariatric Surgery as a Strategy for Improving Outcomes in Nonalcoholic Steatohepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2015.	7.4	3
107	Impact of <i>EGF</i> , <i>IL28B</i> , and <i>PNPLA3</i> polymorphisms on the outcome of allograft hepatitis C: a multicenter study. <i>Clinical Transplantation</i> , 2016, 30, 452-460.	1.6	2
108	The Great Opportunity: Cultivating Scientific Inquiry in Medical Residency. <i>Journal of Infectious Diseases</i> , 2018, 218, S44-S48.	4.0	1

#	ARTICLE	IF	CITATIONS
109	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 523-524.	4.4	1
110	Reply:. Hepatology, 2010, 51, 343-344.	7.3	0
111	Editorial: rethinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 988-989.	3.7	0
112	Growth Hormone Releasing Hormone Reduces Plasma Markers of Immune Activation and Hepatic Immune Pathways in Nonalcoholic Fatty Liver Disease. Journal of the Endocrine Society, 2021, 5, A628-A629.	0.2	0
113	Dietary Heterocyclic Amine Intake and Risk of Esophageal Squamous Cell Carcinoma in Rural Uganda. International Journal of Cancer and Clinical Research, 2021, 8, .	0.1	0
114	Clinicopathologic and prognostic features of hepatocellular carcinoma (HCC) due to metabolic syndrome (MS) compared to chronic liver disease (CLD) and cryptogenic causes (CC).. Journal of Clinical Oncology, 2016, 34, e15616-e15616.	1.6	0
115	Comparing clinicopathologic feature and treatment outcome of patients who underwent surgical resection or liver transplant for nonalcoholic fatty liver disease (NAFLD)-related and non-NAFLD related hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, e16675-e16675.	1.6	0